You are here

Article Text

Article menu
Download PDFPDF
Therapeutics/Prevention
Systematic review
Evidence is weak to support hepatocellular carcinoma screening in chronic liver disease
  1. Simon D Taylor-Robinson1,
  2. Jessica Wong2,
  3. Mary M E Crossey2,
  4. Shahid A Khan2
  1. 1Department of Medicine, Imperial College London, London, UK;
  2. 2Imperial College London, London, UK
  1. Correspondence to: Professor Simon D Taylor-Robinson, Department of Medicine, 10th Floor QEQM Wing, St Mary's Hospital Campus, Imperial College London, South Wharf Street, London W2 1NY, UK; s.taylor-robinson{at}imperial.ac.uk

https://doi.org/10.1136/ebmed-2014-110107

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Kansagara D, Papak J, Pasha AS, et al. Screening for hepatocellular carcinoma in chronic liver disease: a systematic review. Ann Intern Med 2014;161:261–9.OpenUrlCrossRefPubMedWeb of Science

    Context

    Ninety per cent of hepatocellular carcinomas (HCCs) arise from chronic liver disease. Most cases occur in sub-Saharan Africa and Far East Asia, where chronic hepatitis B and C virus infections (HBV and HCV) are the most important risk factors. Excessive alcohol consumption and increasing obesity mean that in the developed world, HCC is also rising steadily.1 In many countries the prognosis for patients with HCC is poor, with 5-year survival rates of less than 5%. In sub-Saharan Africa, the outlook is dismal owing to late …

    View Full Text

    Footnotes

    • Competing interests None.

    • Provenance and peer review Commissioned; internally peer reviewed.